Anti-TNFR2 monoclonal antibody LBL-019 in patients with advanced malignant tumors: A phase I, first-in-human, open-label, multicenter, dose escalation Study.

被引：0
|
作者：
Zhou, Fei
Li, Wei
Chen, Yu
Lin, Jing
Chen, Ling
Zhang, Huishan
Dong, Xiaorong
Tong, Fan
Zhang, Ruiguang
Yin, Yongmei
Liang, Yan
Yang, Nong
Hu, Sheng
Zhuang, Wei
Li, Tao
Cai, Shengli
Zhou, Caicun
机构：
[1] Tongji Univ, Shanghai Pulm Hosp, Dept Med Oncol, Sch Med, Shanghai, Peoples R China
[2] Tongji Univ, Thorac Canc Inst, Sch Med, Shanghai, Peoples R China
[3] Fujian Canc Hosp, Dept Oncol, Fuzhou, Peoples R China
[4] Fujian Canc Hosp, Fuzhou, Peoples R China
[5] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China
[6] Nanjing Med Univ, Dept Oncol, Affiliated Hosp 1, Nanjing, Peoples R China
[7] Hunan Canc Hosp, Lung Gastrointestinal & Oncol Dept, Changsha, Peoples R China
[8] Hubei Canc Hosp, Dept Internal Med Oncol, Wuhan, Peoples R China
[9] Nanjing Leads Biolabs Co Ltd, Nanjing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14580
引用
收藏
页数：1
相关论文
共 50 条
  • [21] First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors
    Vicki L. Keedy
    Heinz-Josef Lenz
    Leonard Saltz
    Jennifer G. Whisenant
    Jordan D. Berlin
    Luis H. Camacho
    Investigational New Drugs, 2018, 36 : 860 - 868
  • [22] Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study
    Reid, Tony
    Oronsky, Bryan
    Scicinski, Jan
    Scribner, Curt L.
    Knox, Susan J.
    Ning, Shoucheng
    Peehl, Donna M.
    Korn, Ron
    Stirn, Meaghan
    Carter, Corey A.
    Oronsky, Arnold
    Taylor, Michael J.
    Fitch, William L.
    Cabrales, Pedro
    Kim, Michelle M.
    Burris, Howard A.
    Lao, Christopher D.
    Abrouk, Nacer E. D.
    Fanger, Gary R.
    Infante, Jeffrey R.
    LANCET ONCOLOGY, 2015, 16 (09): : 1133 - 1142
  • [23] A first-in-human phase Ia/b, open-label, multicentre, dose-escalation study of BI 905711 in patients with advanced gastrointestinal cancers
    Harding, J.
    Hofheinz, R.
    Elez, E.
    Kuboki, Y.
    Geng, J.
    Schmohl, M.
    Dowling, E.
    Feng, Y.
    Rasco, D.
    ANNALS OF ONCOLOGY, 2020, 31 : S145 - S145
  • [24] A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma
    Zonder, Jeffrey A.
    Mohrbacher, Ann F.
    Singhal, Seema
    van Rhee, Frits
    Bensinger, William I.
    Ding, Han
    Fry, John
    Afar, Daniel E. H.
    Singhal, Anil K.
    BLOOD, 2012, 120 (03) : 552 - 559
  • [25] A phase 1, open-label, first-in-human study of TAS2940 in patients with advanced solid tumors
    Ahnert, Jordi Rodon
    Spigel, David R.
    Kremer, Jill
    Jin, Leah
    Benhadji, Karim Adnane
    Gil, Maciej
    Besse, Benjamin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [26] A novel and uniquely designed bispecific antibody (LBL-024) against PD-L1 and 4-1BB in patients with advanced malignant tumors and neuroendocrine carcinoma: A report of safety and robust efficacy of LBL-024 monotherapy in phase I/II, first-in-human, open-label, multicenter, dose escalation/expansion study
    Lu, Ming
    Zhang, Panpan
    Luo, Suxia
    Chen, Jie
    Yang, Jianwei
    Song, Zhengbo
    Li, Yongsheng
    Tang, Ying
    Zhao, Peng
    Liu, Baorui
    Li, Junhe
    Hu, Sheng
    Zhang, Zhiye
    Wu, Lin
    Song, Lijie
    Feng, Xielin
    Shan, Yunfeng
    Liu, Tao
    Cai, Shengli
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [27] Efficacy and safety of tolvaptan in patients with malignant ascites: a phase 2, multicenter, open-label, dose-escalation study
    Kudo, Toshihiro
    Murai, Yoshiyuki
    Kojima, Yoshitsugu
    Uehara, Kenji
    Satoh, Taroh
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (03) : 354 - 362
  • [28] A phase I, first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-1287 administered daily to patients with advanced solid tumors.
    Ben George
    Richards, Donald A.
    Edenfield, William Jeffory
    Warner, Steven L.
    Mouritsen, Lars
    Bishop, Reyna
    Anthony, Stephen Patrick
    Bearss, David
    Vogelzang, Nicholas J.
    Whatcott, Clifford
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [29] A phase I, first-in-human, open-label, dose escalation study of MGD019, an investigational bispecific PD-1 x CTLA-4 DART® molecule in patients with advanced solid tumours
    Sharma, M.
    Sanborn, R. E.
    Cote, G. M.
    Bendell, J. C.
    Kaul, S.
    Chen, F.
    Berezhnoy, A.
    Moore, P.
    Bonvini, E.
    Sumrow, B. J.
    Luke, J. J.
    ANNALS OF ONCOLOGY, 2020, 31 : S704 - S705
  • [30] First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors
    Davis, Elizabeth J.
    Martin-Liberal, Juan
    Kristeleit, Rebecca
    Cho, Daniel C.
    Blagden, Sarah P.
    Berthold, Dominik
    Cardin, Dana B.
    Vieito, Maria
    Miller, Rowan E.
    Dass, Prashanth Hari
    Orcurto, Angela
    Spencer, Kristen
    Janik, John E.
    Clark, Jason
    Condamine, Thomas
    Pulini, Jennifer
    Chen, Xuejun
    Mehnert, Janice M.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (10)
12345